| Ytd | -4.93% | |
| 1y | -11.76% |
| Open | 1.23 | Prev Close | 1.23 | Low | 1.23 | High | 1.35 | Mkt Cap | 208.58M |
| Vol | 3.12M | Avg Vol | 1.01M | EPS | -1.24 | P/E | N/A | Forward P/E | -5.30 |
| Beta | 0.69 | Short Ratio | 8.43 | Inst. Own | 70.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.37 | 200-d Avg | 1.58 | 1yr Est | 5.90 |
CHRS News
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tr
BlackRock Inc. bought a new stake in shares of Coherus Oncology, Inc. (NASDAQ: CHRS) during the unde
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Comp
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Compl
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the p
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second
Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.19) per share which beat the anal
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to ma
REDWOOD CITY, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), toda
Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncol
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQ
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipe
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQT
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.25) per share which beat the anal
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2
Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Pr
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the pu
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market tradin
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some bi
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat